HHS Policy Shifts Control of Popular Wellness Peptides to Small Pharmacies

The Department of Health and Human Services issued a new policy on Tuesday that grants small compounding pharmacies the freedom to produce six specific peptides. This move effectively lifts the enforcement burden for compounds that have long circulated in the gray market. The agency will now exercise discretion, allowing these substances to be made by 503A facilities despite their lack of formal approval.

Health Secretary Robert F. Kennedy Jr., a vocal proponent of peptide therapy, supported the decision. He has previously stated that he uses some of these amino acid chains himself. The six peptides included in the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents claim these compounds treat conditions ranging from ulcerative colitis and insomnia to migraines and metabolic health issues.

Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said the change opens a path for his smaller facility to begin production. His company had avoided making these products for years due to their illegal status for compounding. Fritzler noted that only his smaller 503A site will be eligible, not his larger 503B outsourcing facility. He expects the company will initially focus on just one of the six compounds while it prepares its equipment.

The policy specifically targets small producers, excluding larger outsourcing facilities known as 503Bs. HHS argues that compounding offers a safer alternative to the "research-use-only" peptides sold online by overseas suppliers. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said the decision brings patients under regulatory oversight. He stated that the new framework applies pharmacy standards and adverse event reporting to these products.

Critics argue the administration acted without a typical rulemaking process. Dr. Robert Steinbrook, a health research director at Public Citizen, wrote that the move undermines the FDA. He claimed that allowing unproven substances to be marketed without concern for federal enforcement threatens public health. Steinbrook advised clinicians to inform patients about the risks of contamination and other adverse effects.

The Partnership for Safe Medicines filed a petition last week urging the FDA to disregard its own advisory committee's earlier support for expanded access. Shabbir Safda, the group's executive director, wrote that the decision leaves Americans in a gray area regarding safety. He pointed out that FDA scientists had recommended against unwinding the restrictions due to sparse evidence.

FDA advisory panel members voted in July to support expanded access, though agency scientists recommended against it at the same meeting. The new HHS policy does not change the legal status of the peptides but creates a specific channel for small pharmacies to dispense them. Fritzler said he does not believe all 503A facilities in the country can meet the current consumer demand.